Payment overview · 2025
General Payments
$1,315.62
68 reported records · 20 companies
Healthcare provider profile · identity verified
Myles Howard, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SYRACUSE, NY · NPI 1831152941
Verified facts
What the public records show
CMS Open Payments records show Myles Howard, MD received $1,315.62 in general payments during 2025 across 68 reported records.
GlaxoSmithKline, LLC. accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Zubsolv.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Orexo US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zubsolv as an associated drug or biological on 1867 records involving 794 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Zubsolv by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $166.22 | 12.6% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $137.94 | 10.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $114.97 | 8.7% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $113.99 | 8.7% | 11 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $89.19 | 6.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $88.12 | 6.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.88 | 6.7% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $74.64 | 5.7% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $73.07 | 5.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.85 | 4.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.10 | 4.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.13 | 3.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.78 | 3.2% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $40.70 | 3.1% | 2 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $39.35 | 3.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.40 | 1.6% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $18.48 | 1.4% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $16.64 | 1.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.09 | 1.1% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $14.08 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,315.62 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $166.22 | 7 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $137.94 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $114.97 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $113.99 | 11 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $74.64 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $73.07 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.83 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.83 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.85 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.68 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.10 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.13 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.78 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $40.70 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.60 | 2 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $39.35 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.44 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.44 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $26.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
| Zubsolv zubsolv |
2025 | Zubsolv | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Orexo US, Inc. Exact reporting entity; no affiliate inference |
2025 | Zubsolv open payments reported associated product |
CMS Open Payments — General Payments 1867 supporting records · 794 recipient NPIs · example record 1190507283 |
Zubsolv · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 266 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 146 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 140 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 40 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 127 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 17 |
| Metformin Hcl | Metformin Hcl | 116 | 29 |
| Lisinopril | Lisinopril | 106 | 26 |
| Gabapentin | Gabapentin | 103 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 98 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 13 |
| Tramadol Hcl | Tramadol Hcl | 93 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 22 |
| Glipizide Er | Glipizide | 61 | 15 |
| Omeprazole | Omeprazole | 61 | 18 |
| Fenofibrate | Fenofibrate | 59 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 13 |
| Pregabalin | Pregabalin | 56 | suppressed |
| Clonazepam | Clonazepam | 55 | suppressed |
| Losartan Potassium | Losartan Potassium | 53 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Simvastatin | Simvastatin | 36 | 13 |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 33 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,315.62 · 68 records | GlaxoSmithKline, LLC. | ABRYSVO, ACCRUFER, AREXVY, BRIXADI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FREESTYLE LIBRE 3, IBSRELA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Natroba, Ohtuvayre, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SUBLOCADE, Spinosad, TRELEGY ELLIPTA, TRUMENBA, UBRELVY, VOQUEZNA, Yeztugo, ZAVZPRET, ZEPBOUND, Zubsolv | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error